# Urinary Antispasmodics

This is a subcategory of Genitourinary Agents.

## Formulary

### Preferred

| Preferred         | Generic Name | Quantity | Time (Days) |
| :---------------- | :----------- | :------: | :---------: |
| Gelnique          |              |          |             |
| Myrbetriq Tab     |              |          |             |
| Oxybutynin <sup>QL</sup>        |              |          |             |
| Oxytrol For Women |              |          |             |
| Solifenacin <sup>QL</sup>        |              |          |             |
| Toviaz <sup>BvG</sup>         |              |          |             |

### Non-Preferred

| Non-Preferred         | Generic Name | Quantity | Time (Days) |
| :-------------------- | :----------- | :------: | :---------: |
| Darifenacin <sup>QL</sup>           |              |          |             |
| Fesoterodine          |              |          |             |
| Gemtesa               |              |          |             |
| Myrbetriq Granules <sup>AR</sup>  |              |          |             |
| Tolterodine           |              |          |             |
| Trospium <sup>QL</sup>           |              |          |             |
| Vesicare LS <sup>AR</sup>        |              |          |             |

## Length of Authorizations

365 Days

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **two preferred** drugs with different active ingredients
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**AR** - Vesicare LS: a PA is required for patients younger than 2 years old AND 5 years and older

**AR** - Myrbetriq Granules: a PA is required for patients younger than 3 years old AND 5 years

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=72)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=25)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
